These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7567691)

  • 1. Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid.
    Smets G; Van Ginckel R; Daneels G; Moeremans M; Van Wauwe J; Coene MC; Ramaekers FC; Schalken JA; Borgers M; De Coster R
    Prostate; 1995 Sep; 27(3):129-40. PubMed ID: 7567691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas.
    Dijkman GA; Van Moorselaar RJ; Van Ginckel R; Van Stratum P; Wouters L; Debruyne FM; Schalken JA; de Coster R
    J Urol; 1994 Jan; 151(1):217-22. PubMed ID: 8254818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental studies with liarozole (R 75,251): an antitumoral agent which inhibits retinoic acid breakdown.
    De Coster R; Wouters W; Van Ginckel R; End D; Krekels M; Coene MC; Bowden C
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):197-201. PubMed ID: 1525060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells.
    Wouters W; van Dun J; Dillen A; Coene MC; Cools W; De Coster R
    Cancer Res; 1992 May; 52(10):2841-6. PubMed ID: 1581897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo.
    Van Wauwe J; Van Nyen G; Coene MC; Stoppie P; Cools W; Goossens J; Borghgraef P; Janssen PA
    J Pharmacol Exp Ther; 1992 May; 261(2):773-9. PubMed ID: 1374473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P450-dependent enzymes as targets for prostate cancer therapy.
    De Coster R; Wouters W; Bruynseels J
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity.
    Stearns ME; Wang M; Fudge K
    Cancer Res; 1993 Jul; 53(13):3073-7. PubMed ID: 8319215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice.
    Shalinsky DR; Bischoff ED; Gregory ML; Gottardis MM; Hayes JS; Lamph WW; Heyman RA; Shirley MA; Cooke TA; Davies PJ
    Cancer Res; 1995 Jul; 55(14):3183-91. PubMed ID: 7541715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the oxidative catabolism of retinoic acid in rat Dunning R3327G prostate tumors.
    Krekels MD; Zimmerman J; Janssens B; Van Ginckel R; Cools W; Van Hove C; Coene MC; Wouters W
    Prostate; 1996 Jul; 29(1):36-41. PubMed ID: 8685053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liarozole potentiates the all-trans-retinoic acid-induced structural remodelling in human breast carcinoma MCF-7 cells in vitro.
    Van heusden J; Borgers M; Ramaekers F; Xhonneux B; Wouters W; De Coster R; Smets G
    Eur J Cell Biol; 1996 Sep; 71(1):89-98. PubMed ID: 8884182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole.
    Zeng Q; Smith DC; Suscovich TJ; Gooding WE; Trump DL; Grandis JR
    Clin Cancer Res; 2000 Jun; 6(6):2245-51. PubMed ID: 10873074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of all-trans retinoic acid pharmacokinetics by liarozole.
    Miller VA; Rigas JR; Muindi JR; Tong WP; Venkatraman E; Kris MG; Warrell RP
    Cancer Chemother Pharmacol; 1994; 34(6):522-6. PubMed ID: 7923564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liarozole.
    Bryson HM; Wagstaff AJ
    Drugs Aging; 1996 Dec; 9(6):478-84; discussion 485. PubMed ID: 8972247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells.
    Van heusden J; Wouters W; Ramaekers FC; Krekels MD; Dillen L; Borgers M; Smets G
    Br J Cancer; 1998 Apr; 77(8):1229-35. PubMed ID: 9579827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and beta-carotene in 10T1/2 cells.
    Acevedo P; Bertram JS
    Carcinogenesis; 1995 Sep; 16(9):2215-22. PubMed ID: 7554078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liarozole inhibits human epidermal retinoic acid 4-hydroxylase activity and differentially augments human skin responses to retinoic acid and retinol in vivo.
    Kang S; Duell EA; Kim KJ; Voorhees JJ
    J Invest Dermatol; 1996 Aug; 107(2):183-7. PubMed ID: 8757760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative.
    Gao M; Ossowski L; Ferrari AC
    J Cell Physiol; 1999 Jun; 179(3):336-46. PubMed ID: 10228952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid.
    Van Wauwe J; Coene MC; Cools W; Goossens J; Lauwers W; Le Jeune L; Van Hove C; Van Nyen G
    Biochem Pharmacol; 1994 Feb; 47(4):737-41. PubMed ID: 8129749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole.
    Dockx P; Decree J; Degreef H
    Br J Dermatol; 1995 Sep; 133(3):426-32. PubMed ID: 8546999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
    Debruyne FJ; Murray R; Fradet Y; Johansson JE; Tyrrell C; Boccardo F; Denis L; Marberger JM; Brune D; Rassweiler J; Vangeneugden T; Bruynseels J; Janssens M; De Porre P
    Urology; 1998 Jul; 52(1):72-81. PubMed ID: 9671874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.